

PROVIDER BULLETIN

PROVIDER INFORMATION



December 17, 2015

New Drug-Related Prior Authorization Criteria with Quantity Limit for Natpara®

Effective April 1, 2016, Blue Cross and Blue Shield of Minnesota (Blue Cross) will require prior authorization with a quantity limit requirement for Natpara® (parathyroid hormone).

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring the highest quality, evidence based care for our members. One method for doing so is through the prior authorization process. The primary purpose is to ensure that evidence based care is provided to our members, driving quality, safety, and affordability.

The intent of the Natpara® (parathyroid hormone) prior authorization (PA) program is to encourage appropriate selection of patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies. Criteria will approve doses that are at or below the maximum FDA labeled dose. Doses above the program set limit will be approved if the requested quantity is below the FDA limit and cannot be dose optimized. When the quantity is above the FDA limit, the prescriber must submit documentation in support of therapy for the higher dose for the intended diagnosis.

Pharmacy Prior Authorization Program	Drug Name	Quantity Limits
Natpara® (parathyroid hormone) PA with QL	Natpara®	14 packages of 2 cartridges per 28 days

Products impacted

This PA program applies to commercial lines of business.

New PA criteria will be posted by February 1, 2016, and can be accessed using the Blue Cross provider link.

- Access providers.bluecrossmn.com
- Under Tools And Resources, select Medical policy, then acknowledge the Acceptance statement
- Select Utilization Management
- Select Pharmacy Utilization Management

Questions?

If you have questions, please contact provider services at (651) 662-5200 or 1-800-262-0820.